FDA InspectionTAGI Pharma, Inc.
TAGI Pharma, Inc. – FDA Inspection, Jun 12, 2025
Record Details
This FDA Inspection record concerns TAGI Pharma, Inc., with an inspection on June 12, 2025, issued by the Chicago District Office, covering human drugs.
ID · e8b74b3a-2890-419b-a853-cb77e17a63ba
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1231414
- FDA center
- Human Drugs
- Project area
- Postmarketing Surveillance and Epidemiology: Human Drugs
FDA Citations
1- 21 CFR 314.81(b)(2)Timely submission
Full citation text and observation details available on the Dashboard.
Other FDA inspections of TAGI Pharma, Inc.
1| Date | Classification | Office | Project area |
|---|---|---|---|
| December 13, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Comes with the profile
KRA (KeyPedia Risk Analysis)
How likely the FDA is to take enforcement action in the next 12 months.
Example18-month trend
Form 483 · June 12, 2025
What you get
A document
One file.
- One FDA document, such as a Form 483
- Yours for life in your Library
- Each has its own price
The profile
All the documents, plus intelligence about the company.
- Every TAGI Pharma, Inc. document on file
- The KRA score, which a single document does not include
- Observations and inspection history
Access
This, for every company on KeyPedia.
- Combine profiles in one search
- Search across any modality: products, industry types, drugs, devices and recalls
- Track everything as it changes
- Other agencies too, such as EMA, Health Canada and UK MHRA